Filing Flows › Kyntra Bio (KYNB) › Q4 2025 › vs Q4 2024
Kyntra Bio (KYNB) Q4 2025 vs Q4 2024 (year over year)
Kyntra Bio's revenue fell $1.9M (-59%) from $3.1M in Q4 2024 to $1.3M in Q4 2025.
Kyntra Bio, Q4 2025: revenue $1.3M (-59% year over year), net loss $14.2M, operating cash flow −$18.3M. The chart draws each line against Q4 2024, the increases inside each band.
Every line
| Line | Q4 2025 | Q4 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3M | $3.1M | −$1.9M | -59% |
| Net loss | $14.2M | −$18.0M | $32.2M | — |
| Costs & expenses | $15.5M | $28.3M | −$12.8M | -45% |
| Operating costs | $14.8M | $10.3M | $4.5M | +44% |
| Interest & other, net | $708K | −$25.1M | $25.8M | — |
| Operating cash sources | $19.5M | $30.6M | −$11.1M | -36% |
| Share-based compensation | $1.2M | $178K | $1.0M | +568% |
| Cash used in operations | $18.3M | $30.5M | −$12.1M | -40% |
| Net loss absorbed | $14.2M | −$18.0M | $32.2M | — |
| Working capital & other | $5.3M | $49.0M | −$43.7M | -89% |
Questions
How much did Kyntra Bio's revenue grow year over year in Q4 2025?
Kyntra Bio's revenue fell $1.9M (-59%) from $3.1M in Q4 2024 to $1.3M in Q4 2025.